After surging 8.58 per cent to Rs 575.20 -- its 52-week high level, shares of Cipla finally ended at Rs 557.40, up 5.23 per cent at the BSE.
On the NSE, the stock was up 5.38 per cent to Rs 557.60 at closing.
Led by the rally in the stock, the company's market value surged Rs 2,224.84 crore to Rs 44,754.84 crore.
The stock was the best performer among the blue-chips on both Sensex and Nifty during the day.
Serroflo will substantially improve the affordability of fixed combinations in Europe and help manage health costs for respiratory treatment, the company had said.
The product will be available in the strengths of 120 doses of 25/125 mcg salmeterol/fluticasone and 120 doses of 25/250 mcg salmeterol/fluticasone.